DK2571506T3 - Fremgangsmåder til fremstilling af makrolider og ketolider og mellemprodukter dertil - Google Patents
Fremgangsmåder til fremstilling af makrolider og ketolider og mellemprodukter dertil Download PDFInfo
- Publication number
- DK2571506T3 DK2571506T3 DK11784318.5T DK11784318T DK2571506T3 DK 2571506 T3 DK2571506 T3 DK 2571506T3 DK 11784318 T DK11784318 T DK 11784318T DK 2571506 T3 DK2571506 T3 DK 2571506T3
- Authority
- DK
- Denmark
- Prior art keywords
- formula
- compound
- acid addition
- addition salt
- sodium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (17)
1. Fremgangsmåde til fremstilling af en forbindelse med formlen (I),
_(!)_ eller et farmaceutisk acceptabelt salt deraf, hvor: R10 er hydrogen eller acyl; X er H; og Y er OR7; hvor R7 er monosaccharid, disaccharid, alkyl, arylalkyl eller heteroarylalkyl, der hver eventuelt et substitueret, eller acyl eller C(0)NR8R9; hvor R8 og R9 hver et uafhængigt udvalgt fra gruppen bestående af hydrogen, hydroxy, alkyl, heteroalkyl, alkoxy, aryl, arylalkyl, heteroaryl og heteroarylalkyl, der hver eventuelt er substitueret, og dimethylaminoalkyl, acyl, sulfonyl, ureido og carbamoyl; eller R8og R9 er taget sammen med det forbundne nitrogen for at danne en eventuelt substitueret heterocyklus; eller X og Y er taget sammen med det forbundne carbon for at danne carbonyl; V er C(O), C(=NR11), CH(NR12R13) eller N(R14)CH2; hvor N(R14) er bundet til C-10-carbon; hvor R11 er hydroxy eller alkoxy; R12 og R13 hver er uafhængigt udvalgt fra gruppen bestående af hydrogen, hydroxy, alkyl, alkoxy, heteroalkyl, aryl, arylalkyl, heteroaryl og heteroarylalkyl, der hver eventuelt er substitueret, og dimethylaminoalkyl, acyl, sulfonyl, ureido og carbamoyl; R14 er hydrogen, hydroxy, alkyl, alkoxy, heteroalkyl, aryl, arylalkyl, heteroaryl eller heteroarylalkyl, der hver eventuelt er substitueret, eller dimethylaminoalkyl, acyl, sulfonyl, ureido eller carbamoyl; W er H, F, Cl, Br, I eller OH; A er CH2, C(O), C(0)0, C(0)NH, S(0)2, S(0)2NH eller C(0)NHS(0)2; B er (CH2)n, hvor n er et heltal fra 0 til 10; eller en umættet carbonkæde med 2 til 10 carbonatomer; og C er hydrogen, hydroxy, alkyl, alkoxy, heteroalkyl, aryl, arylalkyl, heteroaryl eller heteroarylalkyl, der hver eventuelt er substitueret, eller acyl, acyloxy, sulfonyl, ureido eller carbamoyl; hvilken fremgangsmåde omfatter (at trinnet med
etahlerinn af kontakt mellem en forbindelse med formlen (III), eller et syreadditionssalt deraf, hvor Q i kombination med oximoxygenet danner et acetal eller ketal, eller Q er tropyl, og et acyleringsmiddel for at danne en forbindelse med formlen (IVt
eller et syreadditionssalt deraf, hvor R er en acylgruppe; (b) trinnet med etablering af kontakt mellem en forbindelse med formlen (IV), eller et syreadditionssalt deraf, og et methyleringsmiddel for at danne en forbindelse med formlen (V)_
eller et syreadditionssalt deraf; og (c) trinnet med etablering af kontakt mellem en forbindelse med formlen (V), eller et syreadditionssalt deraf, og et deoximeringsmiddel for at danne en forbindelse med formlen (II)
eller et syreadditionssalt deraf.
2. Fremgangsmåde ifølge krav 1, hvor R10 er hydrogen.
3. Fremgangsmåde ifølge krav 1 eller 2, hvor X og Y tages sammen med det forbundne carbon for at danne cabonyl.
4. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 3, hvor V er C(O).
5. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvor W er H eller F, fortrinsvis F.
6. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 5, hvor A er CH2.
7. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 6, hvor B er (CH2)n, hvor n er 2 til 6, fortrinsvis 2 til 5, mere fortrinsvis 2 til 4, mere fortrinsvis 2 til 3 eller mere fortrinsvis 3.
8. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 7, hvor C er aminophenyl, fortrinsvis 3-aminophenyl.
9. Fremgangsmåde ifølge krav 1, hvor forbindelsen med formlen (I) er med formlen
eller et farmaceutisk acceptabelt salt deraf.
10. Fremgangsmåde ifølge krav 1, hvor forbindelsen med formlen (I) er med formlen
11. Fremgangsmåde til fremstil ing afen forbindelse med formlen (II);
eller et farmaceutisk acceptabelt salt deraf, hvor R er en acylgruppe; hvilken fremgangsmåde omfatter (a) trinnet med etablering af kontakt mellem en forbindelse med formlen (III),
eller et syreadditionssalt deraf, hvor Q i kombination med oximoxygenet danner et acetal eller ketal, eller Q er tropyl, og et acyleringsmiddel for at danne en forbindelse med formlen (IV)
_(IV)_ eller et syreadditionssalt deraf; (b) trinnet med etablering af kontakt mellem en forbindelse med formlen (IV), eller et syreadditionssalt deraf, og et methyleringsmiddel for at danne en forbindelse med formlen (V)
_(V)_ eller et syreadditionssalt deraf; og (c) trinnet med etablering af kontakt mellem en forbindelse med formlen (V), eller et syreadditionssalt deraf, og et deoximeringsmiddel for at danne en forbindelse med formlen (II).
12. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 11, hvor acyleringsmidlet er et anhydrid.
13. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 12, hvor methyleringsmidlet i trin (b) er methylbromid, methyliodid, dimethylsulfat, methyl p-toluensulfonat eller methylmethansulfonat; fortrinsvis methyliodid.
14. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 13, hvor deoximeringsmidlet i trin (c) omfatter et reduktionsmiddel.
15. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 13, hvor deoximeringsmidlet i trin (c) omfatter en uorganisk svovloxidforbindelse, fortrinsvis natriumhydrogensulfit, natriumpyrosulfat, natriumthiosulfat, natriumsulfit, natriumhydrosulfit, natriummetabisulfit, natriumbisulfit, natriumdithionat, kaliumhydrogensulfit, kaliumthiosulfat, kaliummetabisulfit, eller blandinger deraf, mere fortrinsvis natriummetabisulfit eller natriumbisulfit, eller en kombination deraf, og endnu mere fortrinsvis natriumbisulfit.
16. Fremgangsmåde eller forbindelse ifølge et hvilket som helst af kravene 1 til 15, hvor Q er 2-methoxy-2-propyl, 1-methoxycyclohexyl eller 1-isopropoxycyclohexyl, fortrinsvis 2-methoxy-2-propyl.
17. Fremgangsmåde eller forbindelse ifølge et hvilket som helst af kravene 1 til 16, hvor R er benzoyl.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34666410P | 2010-05-20 | 2010-05-20 | |
| PCT/US2011/037330 WO2011146829A1 (en) | 2010-05-20 | 2011-05-20 | Processes for preparing macrolides and ketolides and intermediates therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2571506T3 true DK2571506T3 (da) | 2017-08-28 |
Family
ID=44992076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11784318.5T DK2571506T3 (da) | 2010-05-20 | 2011-05-20 | Fremgangsmåder til fremstilling af makrolider og ketolider og mellemprodukter dertil |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US9051346B2 (da) |
| EP (1) | EP2571506B1 (da) |
| JP (1) | JP6184319B2 (da) |
| KR (1) | KR101945324B1 (da) |
| CN (2) | CN105198944B (da) |
| AU (1) | AU2011255464C1 (da) |
| BR (1) | BR112012029586A2 (da) |
| CA (1) | CA2799937A1 (da) |
| DK (1) | DK2571506T3 (da) |
| ES (1) | ES2636948T3 (da) |
| HK (2) | HK1181672A1 (da) |
| IL (1) | IL223161A0 (da) |
| PL (1) | PL2571506T3 (da) |
| RU (1) | RU2608390C2 (da) |
| SI (1) | SI2571506T1 (da) |
| WO (1) | WO2011146829A1 (da) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7601695B2 (en) | 2003-03-10 | 2009-10-13 | Optimer Pharmaceuticals, Inc. | Antibacterial agents |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| AU2008316830B2 (en) | 2007-10-25 | 2016-03-17 | Cempra Pharmaceuticals, Inc. | Process for the preparation of macrolide antibacterial agents |
| DK2358379T3 (da) | 2008-10-24 | 2016-03-07 | Cempra Pharmaceuticals Inc | Bioforsvar ved anvendelse af triazolholdige macrolider |
| US9937194B1 (en) | 2009-06-12 | 2018-04-10 | Cempra Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory diseases |
| AU2010292010B2 (en) | 2009-09-10 | 2016-01-07 | Cempra Pharmaceuticals, Inc. | Methods for treating malaria, tuberculosis and MAC diseases |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| US9035072B2 (en) | 2010-04-22 | 2015-05-19 | Vertex Pharmaceuticals Incorporated | Process of producing cycloalkylcarboxamido-indole compounds |
| DK2571506T3 (da) * | 2010-05-20 | 2017-08-28 | Cempra Pharmaceuticals Inc | Fremgangsmåder til fremstilling af makrolider og ketolider og mellemprodukter dertil |
| EP2613630A4 (en) | 2010-09-10 | 2014-01-15 | Cempra Pharmaceuticals Inc | FLUOROCETOLIDES FORMING HYDROGEN LINKS TO TREAT DISEASES |
| WO2013148891A1 (en) | 2012-03-27 | 2013-10-03 | Cempra Pharmaceuticals, Inc. | Parenteral formulations for administering macrolide antibiotics |
| CN103897002A (zh) * | 2012-12-31 | 2014-07-02 | 菏泽市方明制药有限公司 | 一种粗品硫氰酸红霉素制备红霉素a9-肟的方法 |
| US9861616B2 (en) | 2013-03-14 | 2018-01-09 | Cempra Pharmaceuticals, Inc. | Methods for treating respiratory diseases and formulations therefor |
| CN105188712A (zh) | 2013-03-15 | 2015-12-23 | 森普拉制药公司 | 用于制备大环内酯抗菌剂的收敛方法 |
| CA3130061C (en) | 2013-04-04 | 2024-05-28 | President And Fellows Of Harvard College | Macrolides and methods of their preparation and use |
| PL3424534T3 (pl) | 2014-04-15 | 2021-11-22 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
| CN104151382B (zh) * | 2014-08-08 | 2016-09-14 | 广东东阳光药业有限公司 | 一种固态大环内酯的晶型 |
| CN104311611B (zh) * | 2014-08-13 | 2017-01-18 | 广东东阳光药业有限公司 | 一种制备固态大环内酯的方法 |
| CA2963815A1 (en) | 2014-10-08 | 2016-04-14 | President And Fellows Of Harvard College | 14-membered ketolides and methods of their preparation and use |
| CA2980315A1 (en) | 2015-03-25 | 2016-09-29 | President And Fellows Of Harvard College | Macrolides with modified desosamine sugars and uses thereof |
| CN106554381A (zh) * | 2015-09-25 | 2017-04-05 | 苏州鹏旭医药科技有限公司 | 酮内酯类抗生素中间体及其制备方法和应用 |
| TW201811811A (zh) * | 2016-09-02 | 2018-04-01 | 森普拉製藥公司 | 製備氟酮內酯之方法 |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1354753A (en) | 1919-02-11 | 1920-10-05 | E M Lannes | Portable building |
| US4331803A (en) | 1980-06-04 | 1982-05-25 | Taisho Pharmaceutical Co., Ltd. | Novel erythromycin compounds |
| US4474768A (en) | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| US4742049A (en) | 1986-06-04 | 1988-05-03 | Abbott Laboratories | Semisynthetic erythromycin antibiotics |
| KR960000434B1 (ko) * | 1986-12-17 | 1996-01-06 | 다이쇼 세이야꾸 가부시끼가이샤 | 에리스로마이신 a유도체 및 그의 제조 방법 |
| IL99995A (en) | 1990-11-21 | 1997-11-20 | Roussel Uclaf | Erythromycin derivatives, their preparation and pharmaceutical compositions containing them |
| US5985844A (en) | 1992-03-26 | 1999-11-16 | Merck & Co., Inc. | Homoerythromycin A derivatives modified at the 4"-and 8A-positions |
| US5527780A (en) | 1992-11-05 | 1996-06-18 | Roussel Uclaf | Erythromycin derivatives |
| FR2697524B1 (fr) | 1992-11-05 | 1994-12-23 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
| FR2718450B1 (fr) | 1994-04-08 | 1997-01-10 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
| FR2719587B1 (fr) | 1994-05-03 | 1996-07-12 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
| US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| FR2739620B1 (fr) | 1995-10-09 | 1997-12-19 | Roussel Uclaf | Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs |
| US6274715B1 (en) | 1995-11-08 | 2001-08-14 | Abbott Laboratories | Tricyclic erythromycin derivatives |
| FR2742757B1 (fr) | 1995-12-22 | 1998-01-30 | Roussel Uclaf | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments |
| FR2745290B1 (fr) | 1996-02-28 | 1998-04-03 | Roussel Uclaf | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments |
| US5719272A (en) * | 1996-04-02 | 1998-02-17 | Abbott Laboratories | 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives |
| ATE296832T1 (de) | 1996-09-04 | 2005-06-15 | Abbott Lab | 6-o-substituierte ketoliden mit antibakteriellen wirkung |
| KR20010013660A (ko) | 1997-06-11 | 2001-02-26 | 실버스타인 아써 에이. | 9-옥심 에리트로마이신 유도체 |
| US6407074B1 (en) | 1997-06-11 | 2002-06-18 | Pfizer Inc | C-4″-substituted macrolide derivatives |
| HN1998000086A (es) | 1997-06-11 | 1999-03-08 | Pfizer Prod Inc | Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos. |
| HN1998000159A (es) | 1997-10-29 | 1999-02-09 | Monsanto Co | Derivados de 9- amino - 3 ceto eritromicina |
| IL135792A0 (en) | 1997-12-01 | 2001-05-20 | Abbott Lab | 6-o-alkyl derivatives of erythronolide b |
| FR2777282B1 (fr) | 1998-04-08 | 2001-04-20 | Hoechst Marion Roussel Inc | Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments |
| US6020521A (en) | 1998-08-26 | 2000-02-01 | Abbott Laboratories | Macrolide LHRH antagonists |
| US6387885B1 (en) | 1998-08-26 | 2002-05-14 | Abbott Laboratories | 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists |
| FR2785612A1 (fr) | 1998-11-10 | 2000-05-12 | Hoechst Marion Roussel Inc | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments |
| KR100317907B1 (ko) | 1998-11-24 | 2001-12-24 | 김 완 주 | 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법 |
| FR2786188B1 (fr) | 1998-11-24 | 2002-10-31 | Hoechst Marion Roussel Inc | Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments |
| TR200102129T2 (tr) | 1998-12-10 | 2002-01-21 | Pfizer Products Inc. | Karbamat ve karbazat ketolid antibiyotikleri. |
| CZ20012675A3 (cs) | 1999-01-27 | 2002-04-17 | Pfizer Products Inc. | Ketolidová antibiotika |
| CA2411293A1 (en) | 1999-01-28 | 2000-07-28 | Pfizer Products Inc. | Novel azalides and methods of making same |
| JP2000351794A (ja) | 1999-04-08 | 2000-12-19 | Hokuriku Seiyaku Co Ltd | エリスロマイシン誘導体 |
| AR023264A1 (es) * | 1999-04-08 | 2002-09-04 | Hokuriku Pharmaceutical | Derivados de eritromicina |
| US6395710B1 (en) | 1999-04-16 | 2002-05-28 | Kosan Biosciences, Inc. | Macrolide antiinfective agents |
| MXPA01010521A (es) | 1999-04-16 | 2003-08-19 | Johnson & Johnson | Antibacteriales de cetolidos. |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6420535B1 (en) | 1999-06-07 | 2002-07-16 | Abbott Laboratories | 6-O-carbamate ketolide derivatives |
| US6437106B1 (en) | 1999-06-24 | 2002-08-20 | Abbott Laboratories | Process for preparing 6-o-substituted erythromycin derivatives |
| WO2001010878A1 (fr) | 1999-08-06 | 2001-02-15 | Taisho Pharmaceutical Co., Ltd. | Derives d'erythromycine a |
| KR100336447B1 (ko) | 1999-11-24 | 2002-05-15 | 민경윤 | 클라리스로마이신의 개선된 제조방법 |
| JP2001261694A (ja) | 2000-03-06 | 2001-09-26 | Pfizer Prod Inc | ケトライド抗生物質 |
| EP1469008B1 (en) | 2000-03-15 | 2006-08-30 | Hanmi Pharm. Co., Ltd. | Method of preparing a non-pharmaceutical grade clarithromycin |
| NZ523693A (en) | 2000-07-10 | 2004-08-27 | Chiron Corp | Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
| US20020115621A1 (en) | 2000-08-07 | 2002-08-22 | Wei-Gu Su | Macrolide antibiotics |
| GB0031312D0 (en) | 2000-12-21 | 2001-02-07 | Glaxo Group Ltd | Macrolides |
| CA2447600C (en) | 2001-05-18 | 2015-10-20 | Chiron Corporation | Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics |
| WO2003004509A2 (en) * | 2001-07-03 | 2003-01-16 | Chiron Corporation | C12 modified erythromycin macrolides and ketolides having antibacterial activity |
| US20030176327A1 (en) | 2001-10-25 | 2003-09-18 | Cassell Gail Houston | Antibiotics for treating biohazardous bacterial agents |
| US20040019012A1 (en) | 2002-02-22 | 2004-01-29 | Singh Satish K. | Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride |
| KR101048279B1 (ko) | 2002-05-30 | 2011-07-13 | 더 스크립스 리서치 인스티튜트 | 구리 촉매 작용하에서의 아지드와 아세틸렌과의 리게이션 |
| WO2003105775A2 (en) | 2002-06-17 | 2003-12-24 | Epigenesis Pharmaceuticals, Inc. | Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof |
| AR043050A1 (es) | 2002-09-26 | 2005-07-13 | Rib X Pharmaceuticals Inc | Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos |
| ITMI20022292A1 (it) | 2002-10-29 | 2004-04-30 | Zambon Spa | 9a-azalidi ad attivita' antiinfiammatoria. |
| US7601695B2 (en) | 2003-03-10 | 2009-10-13 | Optimer Pharmaceuticals, Inc. | Antibacterial agents |
| WO2004096823A2 (en) | 2003-04-25 | 2004-11-11 | Chiron Corporation | Novel ketolide derivatives |
| CA2523134A1 (en) | 2003-04-25 | 2004-11-11 | Chiron Corporation | Pyridyl substituted ketolide antibiotics |
| SI1628989T1 (sl) * | 2003-05-13 | 2007-06-30 | Glaxo Group Ltd | Nove cikliäśne spojine s 14 in 15 obroäśnimi äśleni |
| WO2005007143A2 (en) | 2003-07-14 | 2005-01-27 | The Board Of Trustees Of The University Of Illinois | Use of makrolides and ketolides for the treatment of tuberculosis |
| US7457520B2 (en) | 2003-07-24 | 2008-11-25 | Time Warner Cable, Inc. | Technique for providing a virtual digital video recorder service through a communications network |
| US7468428B2 (en) | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
| US20060116336A1 (en) | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
| SI1742957T1 (sl) | 2004-04-28 | 2008-04-30 | Alembic Ltd | Postopek za pripravo telitromicina |
| US20080255060A1 (en) * | 2004-05-06 | 2008-10-16 | Sulejman Alihodzic | Ester Linked Macrolides Useful For The Treatment of Microbial Infections |
| EP1794171A2 (en) | 2004-07-28 | 2007-06-13 | Ranbaxy Laboratories, Ltd. | Ketolide derivatives as antibacterial agents |
| GB0424959D0 (en) * | 2004-11-11 | 2004-12-15 | Glaxo Group Ltd | Novel compounds |
| GB0424958D0 (en) * | 2004-11-11 | 2004-12-15 | Glaxo Group Ltd | Novel compounds |
| CN2756842Y (zh) * | 2004-11-12 | 2006-02-08 | 胡济荣 | 沙滩车用一体化发动机 |
| DE602006016231D1 (de) | 2005-01-14 | 2010-09-30 | Glaxosmithkline Zagreb | 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl-y-aminopropyl-azalide mit antimalaria-aktivität |
| DE602006006546D1 (de) | 2005-01-14 | 2009-06-10 | Glaxosmithkline Zagreb | 9a-carbamoyl- und thiocarbamoylazalide mit antimalariawirkung |
| US20070015719A1 (en) | 2005-07-07 | 2007-01-18 | Elan Pharma International Limited | Nanoparticulate clarithromycin formulations |
| WO2007059307A2 (en) | 2005-11-15 | 2007-05-24 | Teva Pharmaceutical Industries Ltd. | Crystalline and amorphous forms of telithromycin |
| EP1954294A2 (en) | 2005-11-23 | 2008-08-13 | Ranbaxy Laboratories Limited | Use of macrolide derivatives for treating acne |
| DOP2006000268A (es) | 2005-12-22 | 2007-07-31 | Pfizer Prod Inc | Agentes antibacterianos |
| CN101045063B (zh) | 2006-03-28 | 2011-01-26 | 广州朗圣药业有限公司 | 注射用克拉霉素水溶性制剂 |
| WO2007143507A2 (en) | 2006-06-05 | 2007-12-13 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted erythromycin analogs |
| CN101129383B (zh) | 2006-08-25 | 2014-04-02 | 天津和美生物技术有限公司 | 含氨基糖苷类抗生素的抗生素复方 |
| US7742562B2 (en) * | 2007-06-27 | 2010-06-22 | Accuray Incorporated | Lower-torso assembly of a treatment couch useable in an X-ray environment |
| EP2214645A4 (en) * | 2007-10-23 | 2013-09-25 | Transave Inc | LIPOSOMAL VANCOMYCIN PREPARATIONS |
| AU2008316830B2 (en) | 2007-10-25 | 2016-03-17 | Cempra Pharmaceuticals, Inc. | Process for the preparation of macrolide antibacterial agents |
| DK2358379T3 (da) * | 2008-10-24 | 2016-03-07 | Cempra Pharmaceuticals Inc | Bioforsvar ved anvendelse af triazolholdige macrolider |
| WO2011008193A1 (en) | 2009-07-13 | 2011-01-20 | Cempra Pharmaceuticals Inc. | Fusidic acid dosing regimens for treatment of bacterial infections |
| AU2010292010B2 (en) | 2009-09-10 | 2016-01-07 | Cempra Pharmaceuticals, Inc. | Methods for treating malaria, tuberculosis and MAC diseases |
| AU2011224238B2 (en) | 2010-03-10 | 2015-11-26 | Cempra Pharmaceuticals, Inc. | Parenteral formulations of macrolide antibiotics |
| CA2793884C (en) | 2010-03-22 | 2019-09-10 | Cempra Pharmaceuticals, Inc. | Crystalline forms of a macrolide, and uses therefor |
| DK2571506T3 (da) | 2010-05-20 | 2017-08-28 | Cempra Pharmaceuticals Inc | Fremgangsmåder til fremstilling af makrolider og ketolider og mellemprodukter dertil |
| US8247394B2 (en) | 2010-06-02 | 2012-08-21 | Cempra Pharmaceuticals Inc. | Methods of treating urethritis and related infections using fusidic acid |
| US20130164351A1 (en) | 2010-08-30 | 2013-06-27 | Cempra Pharmaceuticals Inc. | Methods of treating bacterial infections through pulmonary delivery of fusidic acid |
| EP2613630A4 (en) | 2010-09-10 | 2014-01-15 | Cempra Pharmaceuticals Inc | FLUOROCETOLIDES FORMING HYDROGEN LINKS TO TREAT DISEASES |
| US20140088062A1 (en) | 2011-05-23 | 2014-03-27 | Cem-102 Pharmaceuticals, Inc. | Compositions comprising fusidic acid and packages therefor |
| WO2013148891A1 (en) | 2012-03-27 | 2013-10-03 | Cempra Pharmaceuticals, Inc. | Parenteral formulations for administering macrolide antibiotics |
| US9861616B2 (en) | 2013-03-14 | 2018-01-09 | Cempra Pharmaceuticals, Inc. | Methods for treating respiratory diseases and formulations therefor |
| CN105188712A (zh) | 2013-03-15 | 2015-12-23 | 森普拉制药公司 | 用于制备大环内酯抗菌剂的收敛方法 |
-
2011
- 2011-05-20 DK DK11784318.5T patent/DK2571506T3/da active
- 2011-05-20 CA CA 2799937 patent/CA2799937A1/en not_active Abandoned
- 2011-05-20 CN CN201510604701.0A patent/CN105198944B/zh not_active Expired - Fee Related
- 2011-05-20 KR KR1020127032834A patent/KR101945324B1/ko active IP Right Grant
- 2011-05-20 CN CN201180026739.4A patent/CN102917708B/zh not_active Expired - Fee Related
- 2011-05-20 EP EP11784318.5A patent/EP2571506B1/en not_active Not-in-force
- 2011-05-20 SI SI201131256T patent/SI2571506T1/sl unknown
- 2011-05-20 PL PL11784318T patent/PL2571506T3/pl unknown
- 2011-05-20 US US13/699,020 patent/US9051346B2/en not_active Expired - Fee Related
- 2011-05-20 RU RU2012150753A patent/RU2608390C2/ru not_active IP Right Cessation
- 2011-05-20 BR BR112012029586A patent/BR112012029586A2/pt not_active IP Right Cessation
- 2011-05-20 ES ES11784318.5T patent/ES2636948T3/es active Active
- 2011-05-20 WO PCT/US2011/037330 patent/WO2011146829A1/en active Application Filing
- 2011-05-20 AU AU2011255464A patent/AU2011255464C1/en not_active Ceased
- 2011-05-20 JP JP2013511385A patent/JP6184319B2/ja active Active
-
2012
- 2012-11-20 IL IL223161A patent/IL223161A0/en unknown
-
2013
- 2013-08-02 HK HK13109063.8A patent/HK1181672A1/zh not_active IP Right Cessation
-
2015
- 2015-05-01 US US14/702,004 patent/US20150232500A1/en not_active Abandoned
-
2016
- 2016-06-15 HK HK16106890.0A patent/HK1218919A1/zh not_active IP Right Cessation
-
2018
- 2018-03-06 US US15/913,650 patent/US20190048035A1/en not_active Abandoned
-
2019
- 2019-11-25 US US16/693,978 patent/US20200087335A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130120374A (ko) | 2013-11-04 |
| WO2011146829A1 (en) | 2011-11-24 |
| AU2011255464A1 (en) | 2012-12-13 |
| PL2571506T3 (pl) | 2017-10-31 |
| US20200087335A1 (en) | 2020-03-19 |
| RU2608390C2 (ru) | 2017-01-18 |
| SI2571506T1 (sl) | 2017-12-29 |
| RU2012150753A (ru) | 2014-06-27 |
| US9051346B2 (en) | 2015-06-09 |
| US20190048035A1 (en) | 2019-02-14 |
| KR101945324B1 (ko) | 2019-02-07 |
| BR112012029586A2 (pt) | 2016-08-02 |
| HK1218919A1 (zh) | 2017-03-17 |
| EP2571506A4 (en) | 2014-04-02 |
| EP2571506B1 (en) | 2017-05-10 |
| JP2013527187A (ja) | 2013-06-27 |
| AU2011255464B2 (en) | 2016-06-16 |
| CN102917708B (zh) | 2015-11-25 |
| US20150232500A1 (en) | 2015-08-20 |
| IL223161A0 (en) | 2013-02-03 |
| CN105198944A (zh) | 2015-12-30 |
| HK1181672A1 (zh) | 2013-11-15 |
| AU2011255464C1 (en) | 2017-02-23 |
| CN105198944B (zh) | 2018-06-01 |
| JP6184319B2 (ja) | 2017-08-23 |
| ES2636948T3 (es) | 2017-10-10 |
| CA2799937A1 (en) | 2011-11-24 |
| EP2571506A1 (en) | 2013-03-27 |
| US20130066056A1 (en) | 2013-03-14 |
| CN102917708A (zh) | 2013-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2571506T3 (da) | Fremgangsmåder til fremstilling af makrolider og ketolider og mellemprodukter dertil | |
| DK172636B1 (en) | 6-o-methylerythromycin a derivative | |
| PL213731B1 (pl) | Sposób wytwarzania pochodnej 4"-podstawionej-9-deoksy-9A-aza-9A-homoerytromecyny | |
| Arsic et al. | Macrolides: Properties, Synthesis and Applications | |
| CZ20011512A3 (cs) | Nová makrolidová antibiotika | |
| CZ20011754A3 (cs) | Třináctičlenné azalidy a jejich pouľití jako antibiotika | |
| SK286397B6 (sk) | 2-Halogén-6-O-substituované ketolidové deriváty, ich použitie, spôsob ich prípravy a farmaceutické kompozície s ich obsahom | |
| SK5522000A3 (en) | 3,6-hemiketals from the class of 9a-azalides | |
| EP0124216A1 (en) | C-20- and C-23-modified macrolide derivatives | |
| CA2380455C (en) | 9a-azalides with antibacterial activity | |
| AU2006205828A1 (en) | Erythromycin derivatives as antibacterial agents | |
| WO1999011651A2 (en) | 3-descladinose 6-o-substituded erythromycin derivatives | |
| CZ20032216A3 (cs) | 9a-N[N´-(Fenylsulfonyl)karbamoyl]deriváty 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycinu A a 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolidu A | |
| KR100804439B1 (ko) | 에리트로마이신 유도체의 합성에서 아릴 티오이민을사용하는 방법 | |
| JP2004536075A (ja) | Ｏ−アリルエリスロマイシン誘導体を機能化するためのアリール化方法 | |
| US7435805B2 (en) | O-alkyl macrolide and azalide derivatives and regioselective process for their preparation | |
| Heggelund et al. | Preparation and antibacterial activity of cyclic 2′, 3′-carbamate derivatives of azithromycin | |
| AU1528299A (en) | Chemical synthesis of 6-o-alkyl erythromycin c | |
| MXPA00002216A (en) | 3-descladinose 6-o-substituded erythromycin derivatives | |
| CZ20001319A3 (cs) | Nové 3,6-hemiketaly ze třídy 9a-azalidů | |
| KR20000010800A (ko) | 6-o-치환된 에리트로마이신 화합물 및 이의 제조방법 | |
| CZ20001045A3 (cs) | 3-N-módilikováné 6-O-substituované ketolidové deriváty erytromycinu | |
| CZ438999A3 (cs) | C-4"- substituované makrolidové deriváty |